Takeda Pharmaceutical U.S.A., Inc. 401(k) Review & Grade
Takeda Pharmaceutical U.S.A., Inc. Savings and Retirement Plan
Cambridge, MAManufacturing23,292 active participantsPlan year 2024
Estimate from the plan's Form 5500 filing · How we grade
$11,108Employer $ per active participant
$9,624Employee $ saved per active participant
0.05%Direct admin cost, % of plan assets
$6.2BNet plan assets, end of year
$160,386Average balance per account
Score breakdown
- Employer generosity42.0 / 5084th percentile for employer $ per participant
- Low cost17.6 / 2571th percentile for low admin cost vs. same-size plans
- Employee saving8.3 / 1555th percentile for employee $ per participant
- Plan features3 / 10Default investment
Total score71 / 100 · Grade B
This plan vs. peers
Peers: Manufacturing plans with 10,000+ active participants (151 plans).
| Measure | Percentile |
|---|---|
| Employer $ per participant | 84th |
| Lower admin cost | 71th |
| Employee saving | 55th |
| Peers that auto-enroll | 69% |
Red flags from the filing
No red flags were reported on this filing's compliance questions.
What to do if you're in this plan
- Takeda Pharmaceutical U.S.A. put in about $11,108 per active participant, more than the typical peer ($5,480). Contribute at least enough to collect the full match. Skipping it leaves part of your pay on the table.
- The filing shows total dollars, not the match formula. Ask HR for the Summary Plan Description so you know the exact match and vesting schedule.
- Fund expense ratios aren't in the filing. Look them up in your 404(a)(5) fee disclosure and favor low-cost index or target-date funds.
- Changing jobs? You can usually leave the money in the plan, move it to your new employer's plan, or roll it into an IRA. Don't cash out: you'd owe taxes and possibly a 10% penalty.
The raw numbers from the filing
| Employer contributions | $258,731,300 |
| Participant (employee) contributions | $224,155,330 |
| Other contributions (incl. rollovers in) | $47,229,939 |
| Administrative expenses paid from the plan | $2,971,785 |
| Contract administrator fees | $8,100 |
| Investment advisory & management fees | $924,136 |
| Other admin expenses | $566,266 |
| Benefits paid out | $607,680,840 |
| Net assets, start / end of year | $5.5B / $6.2B |
| Active participants, start / end of year | 23,253 / 23,331 |
| Participants with account balances | 38,538 |
| Auto-enrollment (feature code 2S) | Not reported |
| Auditor | Forvis Mazars, LLP |
| Employer stock held by plan | $9,734,841 |
Largest service providers (Schedule C)
| Fidelity Inv Inst Ops Co., Inc. | $1,501,131 reported compensation |
| Strategic Advisors | $924,136 reported compensation |
| Willis Towers Watson US LLC | $455,362 reported compensation |
Source: DOL EFAST2 Form 5500 filing, acknowledgment ID 20251008163343NAL0003432819001, received 2025-10-08, EIN 13-4013710, plan #001, plan year 2024-01-01 to 2024-12-31. Verify at efast.dol.gov.
Get notified when Takeda Pharmaceutical U.S.A.'s next filing posts
The most generous employers, the worst red flags, and plain-English 401(k) tips. One email a month.